ALC

Alcon Inc.

Fundamental data last updated:June 14, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Instruments & Supplies

Exchange

NYSE

County of HQ

CH

Next Earnings Date

08/18/2026

Business Summary

Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

 


VALUATION

P/E

39.78

Market Cap ($M USD)

$32.45B

Forward P/E

11.43

PEG

0.05

PRICE TO SALES

3.07

PRICE TO BOOK

1.46

EV / EBITDA

17.01

5-Year Average P/E

Free Cash Flow Yield

5.25%

DCF Value

$81.78

Graham Number

$41.47

Price to FCF

19.04

EV to FCF

21.21

Earnings Yield

2.51%

FCF Yield

5.25%

DIVIDEND

Yield

0.54%

Annual Payout

$0.36

Payout Ratio

19.70%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.67

Next Year EPS Growth Estimate

$5.83

Next Year Revenue Growth Estimate

$1.40T

Return on Equity (ROE)

3.69%

FREE CASH FLOW

Operating Margin

12.31%

Debt-to-Equity

0.24

Piotroski F-Score

8

Altman Z-Score

2.62

Return on Invested Capital (ROIC)

4.53%

Current Ratio

2.20

Quick Ratio

1.39

Net Debt to EBITDA

1.74

Interest Coverage

8.52

Gross Profit margin

54.95%

FCF PER SHARE

$3.50

REVENUE PER SHARE

$21.72

Gainseekers Quantitative Analysis

Summary

Alcon Inc. appears to be a compelling opportunity for value investors, with its stock trading below its DCF value and Graham Number. The Forward P/E ratio of 10.67 suggests the market may be underestimating its future earnings potential, especially given the impressive earnings growth forecast. Despite a modest Earnings Yield of 2.68%, the Altman Z-score of 2.52 indicates a reasonable level of financial safety. This combination of undervaluation and growth potential positions Alcon as a potentially attractive investment.

AI Exposure / Tech Reliance

Operating in the Medical Instruments & Supplies industry, Alcon is well-positioned to leverage AI and modern technology to enhance its product offerings. The healthcare sector's increasing reliance on precision and data-driven solutions aligns with Alcon's capabilities. This adaptability could bolster its competitive edge in a rapidly evolving market.

The Bull Case

For GARP investors, Alcon's robust Piotroski F-Score of 8 signals strong financial health and operational efficiency. The company's ROIC of 4.53% and FCF Yield of 5.59% highlight its ability to generate returns and cash flow effectively. With an operating margin of 12.31%, Alcon demonstrates solid pricing power, suggesting it can maintain profitability even in competitive environments. These metrics collectively paint a picture of a company with both growth potential and financial discipline.

The Bear Case

Despite its strengths, Alcon faces challenges with its high Price/Earnings ratio of 37.38, which could deter value investors wary of overvaluation. The Price/Sales ratio of 2.88 and Price to FCF of 17.89 suggest the stock may be priced for perfection, leaving little room for error. Additionally, the stock's significant distance from its 52-week high indicates potential technical overextension, raising concerns about its current market sentiment. These factors could pose risks for investors seeking immediate value.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$81.67

Institutional Ownership %

1-Year Beta

0.70

Insider Buying % (6 Mo)

Distance to 52-Week High

39.01%

Distance to 52-Week Low

7.13%

EARNINGS SURPRISE %

6.25%

50-DAY SMA

$72.58

200-DAY SMA

$77.36

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.